Cargando…

Pegylated recombinant human granulocyte colony‐stimulating factor regulates the immune status of patients with small cell lung cancer

BACKGROUND: Small cell lung cancer (SCLC) is an aggressive disease involving immunodeficiency for which chemotherapy is the standard treatment. Pegylated recombinant human granulocyte colony‐stimulating factor (PEG‐rhG‐CSF) is widely used for primary or secondary prophylaxis of febrile neutropenia (...

Descripción completa

Detalles Bibliográficos
Autores principales:	Sun, Jing, Bai, Hua, Wang, Zhijie, Duan, Jianchun, Li, Jin, Guo, Ruimin, Wang, Jie
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley & Sons Australia, Ltd 2020
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7049512/ https://www.ncbi.nlm.nih.gov/pubmed/32020764 http://dx.doi.org/10.1111/1759-7714.13322

Ejemplares similares

Efficacy and safety of 3 mg pegylated recombinant human granulocyte colony‐stimulating factor as support to chemotherapy for lung cancer
por: Ji, Xiang, et al.
Publicado: (2021)

Effects of pegylated recombinant human granulocyte colony-stimulating factor on lymphocytes and white blood cells of patients with malignant tumor
por: Zhao, Tong, et al.
Publicado: (2023)

Safety and efficacy of pegylated recombinant human granulocyte colony-stimulating factor during concurrent chemoradiotherapy for small-cell lung cancer: a retrospective, cohort-controlled trial
por: Wang, Cunliang, et al.
Publicado: (2022)

Comparison of the effects of pegylated granulocyte-colony stimulating factor and granulocyte-colony stimulating factor on cytopenia induced by dose-dense chemotherapy in breast cancer patients
por: Ashrafi, Farzaneh, et al.
Publicado: (2018)

Clinical observation of the therapeutic effects of pegylated recombinant human granulocyte colony-stimulating factor in patients with concurrent chemoradiotherapy-induced grade IV neutropenia
por: WU, FENG-PENG, et al.
Publicado: (2015)

Development of Site-Specific PEGylated Granulocyte Colony Stimulating Factor With Prolonged Biological Activity
por: Kumari, Monika, et al.
Publicado: (2020)

Peripheral blood stem cell mobilization with pegylated granulocyte colony stimulating factor in children
por: Thakkar, Dhwanee, et al.
Publicado: (2021)

Docetaxel plus ramucirumab with primary prophylactic pegylated-granulocyte-colony stimulating factor for pretreated non-small cell lung cancer
por: Hata, Akito, et al.
Publicado: (2018)

Safety and efficacy of administering reduced doses of pegylated recombinant human granulocyte‐colony stimulating factors in patients treated with cisplatin and etoposide for small cell carcinoma: A retrospective study
por: Liu, Chang, et al.
Publicado: (2021)

Paclitaxel, ifosfamide and cisplatin with granulocyte colony-stimulating factor or recombinant human interleukin 3 and granulocyte colony-stimulating factor in ovarian cancer: a feasibility study.
por: Veldhuis, G. J., et al.
Publicado: (1997)

Granulocyte, granulocyte–macrophage, and macrophage colony-stimulating factors can stimulate the invasive capacity of human lung cancer cells
por: Pei, X-H, et al.
Publicado: (1999)

Granulocyte colony-stimulating factor and leukemogenesis.
por: de Figueiredo, Lorena Lobo, et al.
Publicado: (2004)

Treatment with Molgramostim (Recombinant Human Granulocyte-Macrophage Colony Stimulating Factor, Rhugm-Csf, Mielogen) and Lenograstim (Granulocyte-Colony Stimulating Factor) Improves Experimental Colitis in Rats
por: Papalois, Apostolos E., et al.
Publicado: (2019)

Current status of granulocyte–macrophage colony-stimulating factor in the immunotherapy of melanoma
por: Kaufman, Howard L, et al.
Publicado: (2014)

Preparation and Characterization of Site-Specific Fatty Chain-Modified Recombinant Human Granulocyte Colony Stimulating Factor
por: Wang, Xu-Dong, et al.
Publicado: (2022)

A clinical study of pegylated recombinant human granulocyte colony stimulating factor (PEG-rhG-CSF) in preventing neutropenia during concurrent chemoradiotherapy of cervical cancer
por: Zou, Dongling, et al.
Publicado: (2021)

In vitro and in vivo analysis of the effects of recombinant human granulocyte colony-stimulating factor in patients.
por: Bronchud, M. H., et al.
Publicado: (1988)

Development of Wolffia arrhiza as a Producer for Recombinant Human Granulocyte Colony-Stimulating Factor
por: Khvatkov, Pavel, et al.
Publicado: (2018)

An open-label pilot study of recombinant granulocyte-colony stimulating factor in Friedreich’s ataxia
por: Kemp, Kevin C., et al.
Publicado: (2022)

Granulocyte-colony stimulating factor (G-CSF) and granulocyte-macrophage colony stimulating factor (GM-CSF) for sepsis: a meta-analysis
por: Bo, Lulong, et al.
Publicado: (2011)

CODE chemotherapy with and without granulocyte colony-stimulating factor in small-cell lung cancer.
por: Fukuoka, M., et al.
Publicado: (1997)

Establishment of the first international standard for PEGylated granulocyte colony stimulating factor (PEG-G-CSF): Report of an international collaborative study
por: Wadhwa, Meenu, et al.
Publicado: (2015)

Granulocyte Colony-Stimulating Factor in Amniotic Fluid
por: Raynor, B. Denise, et al.
Publicado: (1995)

The importance of the granulocyte-colony stimulating factor in oncology
por: CETEAN, SÎNZIANA, et al.
Publicado: (2015)

Granulocyte Colony-stimulating Factor-associated Aortitis
por: Nishioka, Hiroaki, et al.
Publicado: (2023)

Thrombin Stimulates Synthesis of Macrophage Colony-Stimulating Factor, Granulocyte-Macrophage Colony-Stimulating Factor and Granulocyte Colony-Stimulating Factor by Human Proximal Tubular Epithelial Cells in Culture
por: Shimaya, Yuko, et al.
Publicado: (2012)

Clinical significance of primary prophylactic pegylated‐granulocyte‐colony stimulating factor after the administration of ramucirumab plus docetaxel in patients with previously treated non‐small cell lung cancer
por: Mouri, Atsuto, et al.
Publicado: (2019)

Induction of T-cell mitogenic unresponsiveness by recombinant human granulocyte colony-stimulating factor – a reply
por: Reyes, E, et al.
Publicado: (2000)

Recombinant human granulocyte colony-stimulating factor. Effects on hematopoiesis in normal and cyclophosphamide-treated primates
Publicado: (1987)

Severe Drug-Induced Agranulocytosis Successfully Treated with Recombinant Human Granulocyte Colony-Stimulating Factor
por: Kubota, Yohei, et al.
Publicado: (2018)

MORPHOLOGIC CHANGES OF NEUTROPHILS IN MYELODYSPLASTIC SYNDROME TREATED WITH RECOMBINANT HUMAN GRANULOCYTE COLONY‐STIMULATING FACTOR
por: Toyama, Keisuke, et al.
Publicado: (1988)

Hematologic and Cytogenetic Findings in Myelodysplastic Syndromes Treated with Recombinant Human Granulocyte Colony‐stimulating Factor
por: Ohyashiki, Kazuma, et al.
Publicado: (1989)

A novel PEGylated form of granulocyte colony-stimulating factor, mecapegfilgrastim, for peripheral blood stem cell mobilization in patients with hematologic malignancies
por: Wen, Jingjing, et al.
Publicado: (2023)

Psoriasiform eruption triggered by recombinant granulocyte-macrophage colony stimulating factor (rGM-CSF) and exacerbated by granulocyte colony stimulating factor (rG-CSF) in a patient with breast cancer.
por: Cho, S. G., et al.
Publicado: (1998)

The Status of the EGFR T790M Mutation is associated with the Clinical Benefits of Osimertinib Treatment in Non-small Cell Lung Cancer Patients: A Meta-Analysis
por: Zhao, Zhe, et al.
Publicado: (2020)

Effects of the in vivo Administration of Recombinant Human Granulocyte Colony‐stimulating Factor Following Cytotoxic Chemotherapy on Granulocytic Precursors in Patients with Malignant Lymphoma
por: Ema, Hideo, et al.
Publicado: (1989)

Phase I/II study of recombinant human granulocyte colony-stimulating factor in patients receiving intensive chemotherapy for small cell lung cancer.
por: Bronchud, M. H., et al.
Publicado: (1987)

Granulocyte-macrophage colony-stimulating factor as an immune-based therapy in HIV infection
por: Brown, Pierre Antoine, et al.
Publicado: (2005)

Different effects of granulocyte colony-stimulating factor and erythropoietin on erythropoiesis
por: Chen, Tzu-Lin, et al.
Publicado: (2018)

In Vivo Administration of Recombinant Human Granulocyte Colony-Stimulating Factor Increases the Immune Effectiveness of Dendritic Cell-Based Cancer Vaccination
por: Shimodaira, Shigetaka, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_tqq6c9hqje22n2op0pqubs0dum